Rapid, accurate UTI diagnosis and AST—in as little as 2 hours—so clinicians can prescribe the right treatment the first time.
Rapid, accurate UTI diagnosis and AST—in as little as 2 hours—so clinicians can prescribe the right treatment the first time.
Urinary tract infections (UTIs) affect over 20 million people in the U.S. and more than 200 million worldwide each year — the vast majority of them women.
When left untreated or mistreated, UTIs can spread to the bloodstream and cause urosepsis. In the U.S. alone, this occurs over 200,000 times annually and leads to more than 13,000 deaths, making UTIs the fourth most deadly infectious disease.
Diagnosing UTIs still depends on 1950s-era Petri dish culture tests, which take 2–4 days to produce results, including antibiotic susceptibility testing (AST). With more than half of UTIs now resistant to common antibiotics, this delay leaves patients at risk.
Most suspected cases are never formally tested. Instead, patients are given a “best guess” prescription — and in more than 50% of cases, this initial treatment fails, prolonging discomfort and driving antibiotic resistance, a serious and escalating global threat.
The situation is made worse by frequent sample contamination, which often requires re-sampling and restarts the process from the beginning.
Urinary Technologies Corp (UTC) has created an antibody-based test that pinpoints the microbial cause of infection and identifies the most effective antibiotics.
With patented assays and low-cost disposable cartridges, providers can run multiple antibody tests and AST simultaneously, confirming which of the ten microbial species is responsible for over 99% of UTIs — and delivering results in as little as two hours, far faster and more reliable than traditional cultures.
Public health and start-up promotion
Med tech business development, R&D and patent law; technology commercialization
Clinical practice and lab management, focusing on clinical testing, from assay performance to bedside care
Microfluidic diagnostics development; serial diagnostics entrepreneur
Regulatory affairs and pediatric infectious diseases; former FDA Director
Former managing Director and Senior Research Analyst following medical technology companies at Piper Jaffray; managed many IPOs
Expertise building and scaling healthcare technology start-ups, including achieving successful company exits